Study Shows Bivalent RSV Vaccine Candidate Provides Protection for Older Adults
The RSVpreF vaccine candidate consists of 2 prefusion F proteins selected to optimize protection against RSV A and B.
Respiratory Diseases/Disorders
Ensifentrine Improves Lung Function, Cuts COPD Exacerbations in Late Stage Trial
Ensifentrine (RPL554) is a first-in-class, dual phosphodiesterase (PDE) 3 and 4 inhibitor with combined bronchodilator and anti-inflammatory actions.
Novel Oral Drug Combo Fast Tracked for Obstructive Sleep Apnea
The designation is supported by data from the phase 2 MARIPOSA study, which included adults with mild to moderate OSA.
Homeopathic Spray for Snoring Recalled Due to Microbial Contamination
SnoreStop NasoSpray is a nasal spray used to temporarily help stop or reduce symptoms of nonapneic snoring.
Nasal Therapy Improves Chronic Sinusitis Symptoms, Inflammation
OPN-375 is currently marketed under the brand name Xhance for the treatment of nasal polyps in patients 18 years of age and older.
FDA Authorizes Direct-to-Consumer Test to Detect COVID-19, Influenza, and RSV
The test is the first non-prescription multi-analyte COVID-19 test that allows individuals to test nasal swab samples self-collected at home.
Long-COVID Lung Disease: Researchers Characterize 3 Phenotypes
Can long-COVID lung diseases be better understood and classified via analysis of abnormalities seen on transbronchial lung cryobiopsies?
Efzofitimod Granted Orphan Drug Status for Systemic Sclerosis
In preclinical studies, efzofitimod was found to prevent inflammation and fibrosis in multiple animal models of systemic sclerosis and idiopathic pulmonary fibrosis.
Sabizabulin Cuts COVID-19 Death; Trial Stopped Early Due to Efficacy
The phase 3 trial included approximately 210 patients hospitalized with moderate to severe COVID-19 (WHO ≥4) who were at high risk for ARDS and death.
Tocilizumab Gets Priority Review for Treatment of Hospitalized COVID-19 Patients
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
- Loading...
Loading...
Next post in News
Loading... 
Loading...